Simulations Plus Has Acquired Pro-ficiency!

Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum

Acquisition doubles the Company’s TAM to $8 billion

Expected to be accretive to fiscal 2025 EPS

Conference call at 5:00PM ET to discuss transaction

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries (“Pro-ficiency”), a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development. Simulations Plus acquired Pro-ficiency from QHP Capital, L.P. (management company for NovaQuest Private Equity) (“QHP Capital”) and Pro-ficiency’s minority shareholders for approximately $100 million in cash.

The transaction expands Simulations Plus’ presence across the drug development continuum from establishing pre-clinical protocols to product commercialization, providing pharmaceutical and biotech companies with an end-to-end offering that now includes clinical trial operations, medical affairs and commercial market launches. Pro-ficiency’s suite of software and services, developed with AI technologies, is a highly complementary and synergistic addition to Simulations Plus’ platform by expanding its capabilities to enhance clinical trial and launch training, data analytics and outcomes.

“We are thrilled to announce the expansion of our suite of drug discovery and R&D solutions with this strategic acquisition of Pro-ficiency,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “This transaction brings together two businesses, each with complementary expertise and services that are grounded in science and focused on applying advanced technologies like AI to enhance actionable data analytics. Together, we will continue to assist our clients in improving their drug development return on investment and patient care delivery. With the integration of Pro-ficiency’s immersive simulation-enabled learning, data-driven insights, and medical communications platforms, we are approximately doubling our total addressable market by unlocking the significant growth potential of a $4 billion market opportunity, which is incremental to our $4 billion biosimulation market.

“This acquisition not only deepens our client engagement capabilities and relationships but also presents meaningful cross-selling opportunities to our shared customer base in life sciences. By further expanding our portfolio of critical solutions for efficacious and cost-efficient drug development and commercialization, we believe this acquisition gives us a distinct competitive advantage and will significantly enhance our ability to drive innovation and success within the sector. Furthermore, the transaction is expected to be accretive to our fiscal 2025 EPS,” concluded O’Connor.

Michael Raymer, Chief Executive Officer of Proficiency, added, “We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations within the pharmaceutical and biotech community. Both teams approached this transaction with a growth mentality. We look forward to leveraging Simulations Plus’ specialized offerings and business development infrastructure to expand our combined market reach. Finally, our operations are complementary, our cultures are aligned, and together we believe we can elevate the performance of our mutual clients as well as attract new ones with our end-to-end solutions.”

QHP Capital made its original investment in Pro-ficiency in 2021. Pro-ficiency completed the acquisitions of Fugitive Labs, LLC in 2022 and Compass Group Partners in 2023. “We are very pleased with the growth and innovation we have seen these past few years at Pro-ficiency and we are excited to see them continue to improve clinical development as part of the Simulations Plus offering,” said Michael Sorensen, Partner at QHP Capital.

Strategic Rationale

  • Expands Simulations Plus’ presence along the drug development value chain, leveraging its scientific skills, drug development expertise, data management acumen, predictive analytics and biosimulations capabilities
  • Broadens and differentiates Simulations Plus’ holistic offering to include clinical trial operations, medical affairs, and communications, strengthening its overall value proposition to life sciences customers
  • Doubles total addressable market (TAM), adding $4 billion of clinical simulations training, analytics and medical communications
  • Provides meaningful cross-selling opportunities to a shared target customer base in life sciences
  • Broadens Simulations Plus’ platform and accelerates scale, increasing aperture for continued M&A strategy and improving right-to-win as a strategic partner of choice

Key Terms of the Transaction

The transaction is being funded from existing cash and investment resources. “With approximately $119 million in cash and investments available, this acquisition allows us to utilize the capital from our August 2020 follow-on public offering,” said Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus. “Following the acquisition, we remain well-capitalized with no debt, have strong free cash flow, and will continue our capital allocation strategy and corporate development initiative to seek additional opportunities for strategic acquisitions, investments, and partnerships.”

Additional information about the transaction, including a copy of the purchase agreement and an investor presentation will be provided in a Current Report on Form 8-K to be filed by Simulations Plus today with the U.S. Securities and Exchange Commission and will be available at www.sec.gov .

Procopio acted as legal counsel for Simulations Plus and Wyrick Robbins acted as legal counsel for Pro-ficiency and the sellers of Pro-ficiency.

Webcast and Conference Call Details

Shawn O’Connor, Chief Executive Officer of Simulations Plus; Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus; and Michael Raymer, Chief Executive Officer of Pro-ficiency, will host a conference call and webcast today at 5 p.m. Eastern Time to discuss the details of the transaction and to answer questions. The call may be accessed by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call The webcast will be available on our website under Conference Calls & Presentations . A replay of the webcast will be available on the website approximately one hour following the call.

About Simulations Plus, Inc.

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com . Follow us on LinkedIn YouTube .

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update .

About Pro-ficiency

Based in Raleigh, NC, Pro-ficiency is a leading provider of simulation-based learning, intelligence and compliance solutions for life sciences. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual simulations, market intelligence and compliance resources, and real-time data & predictive analytics. Combined with AI-based engagement tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk and market intelligence for leaders. Learn more at pro-ficiency.com.

About QHP Capital

QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP Capital spun out of NovaQuest Capital Management, which was formed in 2000 with the vision of building an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science and healthcare expertise. QHP benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing QHP’s portfolio companies. QHP continues as the investment manager for NovaQuest Private Equity funds. For more information, please visit www.qhpcapital.com .

Forward-Looking Statements

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Pro-ficiency business with our own, as well as expenses we may incur in connection therewith, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Simulations Plus IR or Media
Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com

Pro-ficiency Appoints Markus Saba, Pharmaceutical Industry Veteran, to Board of Directors

DURHAM, N.C., April 18th, 2024 – Pro-ficiency, a leading provider of simulation-based training and compliance solutions for life sciences, today announced the appointment of Markus Saba to its Board of Directors.

Saba brings a distinguished career spanning over 25 years at Eli Lilly and Company, responsible for successful launches and global management of iconic brands like Prozac, Cymbalta, and Cialis. His proven track record in global healthcare marketing, coupled with extensive geographic expertise, will be instrumental in propelling Pro-ficiency’s vision for innovation and global expansion.

“Markus Saba’s appointment to our Board is a significant milestone,” said Michael Raymer, CEO of Pro-ficiency. “His unparalleled experience and strategic insights will be invaluable as we expand our capabilities to support commercial drug development and launch.”

Beyond his corporate achievements, Saba is also a dedicated educator. For the past six years, he has served as a distinguished professor at the UNC Kenan-Flagler Business School, shaping the next generation of healthcare leaders. His commitment to fostering innovation is evident in his role as Executive in Residence for the Center for the Business of Health.

“I am honored to contribute to Pro-ficiency’s mission to drive progress in life sciences through the strategic integration of technology and expertise,” said Saba. “Pro-ficiency’s dedication to innovation aligns perfectly with my passion for positive change in healthcare. I look forward to leveraging my experience to support the company’s pursuit of excellence and global impact.”

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based learning, intelligence and compliance solutions for life sciences. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual simulations, market intelligence and compliance resources, and real-time data & predictive analytics. Combined with AI-based engagement tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk and market intelligence for leaders. Learn more at pro-ficiency.com.

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Pro-ficiency has been named a winner of the ‘TBJ Fastest 50’ award by the Triangle Business Journal

DURHAM, N.C., November 9th, 2023 – The Triangle Business Journal has named Pro-ficiency a winner of the ‘TBJ Fastest 50 award’, placing Pro-ficiency 31st out of 50 recipients. This award recognizes the 50 fastest-growing private companies in the Triangle region of North Carolina.

Pro-ficiency is a leading provider of simulation-based training solutions in life sciences. By using a proprietary simulation approach combined with deep subject matter expertise, learners achieve understanding and life science leaders gain insight into learner competency and potential risk areas.

Pro-ficiency’s inclusion on the Fastest 50 list is a testament to the company’s rapid growth and its innovative approach to simulation-based training. The company’s solutions enable learners to achieve deep understanding and competency in complex life science concepts, while also providing life science leaders with critical insights into their teams’ performance.

“We are honored to be named among the Triangle Business Journal’s Fastest 50,” said Michael Raymer, CEO of Pro-ficiency. “This recognition is a testament to our team’s dedication to developing innovative solutions that help our customers achieve their goals.”

Pro-ficiency recently acquired Compass Group Partners, a prominent family of companies specializing in medical communications for the life sciences industry. This acquisition has expanded Pro-ficiency’s capabilities into the medical affairs and commercial space, opening new avenues for innovation across all service offerings of the combined company. See the press release to learn more: https://pro-ficiency.newswire.com/news/pro-ficiency-acquires-compass-group-partners-and-affiliated-assets-22059994

With its continued growth and innovation, Pro-ficiency is well-positioned to continue leading the way in simulation-based training for the life sciences industry.

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Combined with protocol optimization, process visualization tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk intelligence for leaders. Learn more at pro-ficiency.com.

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Brad Stefanovic, Clinical Operations and Innovation Leader, Joins Pro-ficiency

DURHAM, N.C., October 19, 2023 – Pro-ficiency, a leading provider of simulation-based training solutions in life sciences, has appointed Brad Stefanovic to lead the organization’s clinical trial innovation efforts. As a former Clinical Operations leader, Stefanovic brings a unique perspective on challenges facing clinical study operations, including how Pro-ficiency can address those issues. In addition, as a former advocate of Pro-ficiency solutions, he can convey the power of simulation-based training solutions from his real-world experience.

“It’s unique to find a team member that has not only talked about the need for change in our profession, but has been active in driving change for years,” said Jenna Rouse, Chief Clinical Markets Officer. “His deep understanding of the challenges facing clinical study operations, combined with his passion for innovation, make him the ideal person to lead our efforts in helping clients to proactively manage risk and improve the efficiency and effectiveness of their clinical trials.”

Brad Stefanovic brings over 17 years of experience in the clinical research industry to Pro-ficiency. He has held senior leadership positions at several leading pharmaceutical companies and contract research organizations (CROs), where he has overseen all aspects of clinical trial design, execution, and management. Stefanovic is also a recognized expert in the use of simulation and modeling to improve the efficiency and effectiveness of clinical trials.

“We are delighted to welcome Brad to the Pro-ficiency team,” said Michael Raymer, CEO of Pro-ficiency. “Brad’s deep expertise spanning from clinical research through commercialization make him the ideal person to lead our efforts in bringing simulation-based training solutions to clients. We are confident that Brad will play a key role in driving client quality through his ability to bridge the gap between theory and practice.”

Stefanovic holds a PhD in Physiology from the University of the Sunshine Coast in Australia and was Alumni of the year in 2022.

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Combined with protocol optimization, process visualization tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk intelligence for leaders. Learn more at pro-ficiency.com.

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Pro-ficiency Acquires Compass Group Partners and Affiliated Assets

DURHAM, N.C., June 13th, 2023 – Pro-ficiency, the leading provider of simulation-based training solutions for clinical trials, has announced its acquisition of Compass Group Partners, a prominent family of companies specializing in medical communications for the life sciences industry. This strategic acquisition will expand simulation-based technologies into the medical affairs and commercial space, opening new avenues for innovation across all service offerings of the combined company.  

By integrating Compass Group Partner’s expertise with Pro-ficiency’s advanced simulation technology, the combined company is now able to offer immersive simulation solutions to address the complexities of the medical affairs and commercial markets. Through interactive simulations, professionals in the field will gain practical experience to optimize diagnosis, treatment selection, and patient monitoring.  

“The acquisition aligns with Pro-ficiency’s vision to revolutionize drug development by bridging the gap between theory and practice,” said Pro-ficiency’s CEO, Michael Raymer. “There is a proven demand for simulation in the markets that Compass Group Partners serves. Combining Pro-ficiency’s unique simulation methodology with their medical communication expertise will create revenue expansion opportunities for the new entity, and ultimately contribute to the delivery of safe and effective drugs to patients worldwide”.

“I founded Caravel Group, and then our parent company Compass Group Partners, to serve as a true strategic and innovation partner to our clients in the life sciences industry,” said Murry Alper, Pro-ficiency’s new Chief Commercial Markets Officer. “This partnership will allow us to bring a new dimension of simulation and analytics to medical affairs and commercial clients. Together, we can revolutionize how professionals acquire critical information while broadening our reach and achieving a measurable impact”.

“This union has created a unique organization in life sciences with an extensive global network, deep expertise across the drug development and commercialization continuum. The solutions suite is grounded in elegant technology poised to set a new standard in this space. The growth and innovation potential are very exciting”, said Renie Dornbusch, Pro-ficiency’s new Chief Commercial Operations Officer.

Compass Group Partners is led by Murry Alper and Renie Dornbusch and serves as the parent company for the Caravel Group Medical Communications, Eclipse Event Management, Zuma Medical Communications and the Panorama KOL Management Platform. The full Compass Group Partners team, assets and client roster, will remain intact to ensure client continuity, but will merge with the Pro-ficiency service suite to bolster capabilities and expertise for all clients across the combined organization.

The Compass Group Partners companies and collection of services will be consolidated under the Caravel Group name.

This is the second acquisition for Pro-ficiency since their funding by QHP Capital (management company for NovaQuest Private Equity) in 2021. 

About Compass Group Partners

Compass Group Partners was established in 2006 as a full service marketing and communications agency in life sciences. Acquiring Eclipse Meeting Productions in 2013 and merging with Zuma Clinical Communications in 2014, the combined family of companies delivers on active partnerships with many of the top 10 global pharmaceutical companies. They are known for creating impactful, value-based and customer-centric solutions that support drug development and commercialization from development to commercialization.

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Combined with protocol optimization, process visualization tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk intelligence for leaders. Learn more at proficiency3.wpengine.com.

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Pro-ficiency Launches Pf Library to Expand Study Training Service Suite

Pro-ficiency is excited to announce the launch of Pf Library, an innovative online document hosting center that provides convenient access to relevant study resources within the Pro-ficiency platform.  Pf Library seamlessly integrates with the Pro-ficiency training portal, providing a comprehensive platform for training and supporting sites, study teams and Sponsors.

Pf Library offers study team managed document hosting functionality for convenient 24/7 access to relevant study resources and documents. The library offers unlimited file storage capabilities for virtually any type of file, providing clients with flexibility to upload any study-relevant resources including: study manuals, guides, templates, standard operating procedures (SOPs), press releases, webinars, videos, and more.

Each client-managed portal offers optional automatic notifications to learners when new or updated resources are available. Additionally, Pf library has the capability to track utilization and viewer metrics.

“Giving sites a single source for study-related guidance was a natural evolution for Pro-ficiency” said Michael Raymer, CEO of Pro-ficiency. “But we wanted to improve on solutions already available on the market. What we have released with Pf Library is a platform that is easy to access, easy to manage, and easy to navigate, all without complex user fees. When we can remove barriers for sites to access study critical information, we all win.”

For more information please visit our website: https://www.pro-ficiency.com/performance-management-platform

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Combined with protocol optimization, process visualization tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk intelligence for leaders. Learn more at pro-ficiency.com

Pro-ficiency Releases Simulation-Based Good Clinical Practice (GCP) Training Program

DURHAM, N.C., March 23rd, 2022 – Pro-ficiency has launched a new Good Clinical Practice (GCP) Simulation training program. This program is immediately available to the public after the publication of this press release for free.

The goal of this interactive simulation-based program is to set a new standard for GCP training compliance and competency development, while also facilitating a more effective, more enjoyable, and less time-consuming learning experience.

The Pro-ficiency GCP Simulation program immerses learners in a cutting-edge adaptive learning environment, building critical thinking and decision-making skills needed to apply GCP principles in the real world. Participants play the roles of study coordinator, investigator, sub-investigator, research nurse, and study monitor/CRA in a variety of simulated scenarios, practicing the application of GCP concepts in a safe environment so they can apply the tenets of good clinical practice in their real world setting.

This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.

For more information, please visit: http://pro-ficiency.com/gcp-sign-ups-public-enrollment

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, including turn-key customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Learn more at https://www.pro-ficiency.com.

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Pro-ficiency has been selected as a ‘Top Ten Tech Startup to Watch in 2022’ by the NC Tech Awards

The NC Tech Awards has named Pro-ficiency as one of the Top Ten Tech Startups to Watch of 2022. This award signifies the innovative progress Pro-ficiency has made, and the potential for further success and expansion in 2023 and beyond.

Pro-ficiency is a next-generation learning engine specializing in life sciences. By using a proprietary simulation approach combined with deep subject matter expertise, learners achieve understanding and life science leaders gain insight into learner competency and potential risk areas.

Michael Raymer, Pro-ficiency’s CEO, said “One of the biggest indicators of future success is recognition of progress, with this NC Tech Award confirming what we’ve known for years, that Pro-ficiency’s proprietary simulation-based approach is the future of training for clinical trials.”

With the clinical arena shifting towards a hybrid-virtualized approach, remote training platforms that can ensure consistent protocol understanding across geographies and languages are essential for driving study compliance and enrollment. Pro-ficiency’s simulation-based training is positioned to change the future of clinical trials by providing engaging training that generates robust performance metrics. This evolved approach drives proactive risk management for sponsors and CROs, improves enrollment, and reduces protocol deviations for studies in any phase, and any therapeutic area.

 

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, including turn-key customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Learn more at proficiency3.wpengine.com.

Pro-ficiency Launches New Solution: Pro-Active Protocol

Pro-ficiency announced today the launch of Pro-Active Protocol, a unique and proprietary protocol optimization methodology that applies simulation to visually represent the study operational flow. 

This expansion complements the organization’s current scope of training services by providing studies with an essential resource to vet the protocol with study teams, regulatory agencies and patients prior to protocol finalization. The solution can be rapidly produced and updated as it is intended to shed light on protocol inconsistencies and gaps so study teams can adjust and revise. 

With the end goal of a better-designed study, Pro-Active Protocol integrates seamlessly with Pro-ficiency’s existing simulation-based protocol modules or can serve as a stand-alone resource, to increase study and site team understanding of the study requirements upon study start-up.

Beth Harper, Pro-ficiency’s Chief Learning Officer, said “One of the biggest challenges in clinical trials is developing a well designed protocol that sites can operationalize. This tool has the power to help sponsors identify possible inconsistencies and challenges before they turn into deviations, it improves the site’s ability to evaluate feasibility, and facilitates a more patient-centric drug development process. This could be one of the easiest, quickest and most effective ways to positively impact a clinical study from the start”.

Pro-ficiency’s Pro-Active Protocol solution is available immediately for studies in any phase and in any therapeutic area. To learn more about our new solution visit: http://proficiency1.wpenginepowered.com/pro-active-protocol

 

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, including turn-key customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Learn more at proficiency3.wpengine.com.

 

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420

Pro-ficiency Acquires Fugitive Labs

Pro-ficiency announces the acquisition of all life sciences intellectual property and the associated team of Fugitive Labs, a full-service nationwide product development firm. This acquisition significantly increases Pro-ficiency’s platform and product development capabilities, which will serve to increase the organization’s competitive advantage in clinical trials performance management. The expanded development team will foster Pro-ficiency’s ability to deliver on a robust development pipeline for years to come.

“The Fugitive team is an incredible addition for us,” said Pro-ficiency CEO, Michael Raymer. “It’s rare to find a product team that understands clinical trials and also develops beautiful, simple, and highly functional user experiences. To have the Fugitive team fully dedicated to innovation within Pro-ficiency is going to keep us lightyears ahead of others in our space.”

The Fugitive Labs team is led by Erik Guffrey, Fugitive Labs CEO, now Pro-ficiency’s Chief Technology Officer. Mr. Guffrey brings a team of product developers with him to focus on building and enhancing the Pro-ficiency suite of products and services. One notable member of the team is Grant Fowler, co-founder of Fugitive, joining Pro-ficiency as Senior Vice President of Engineering. Having over 9 years of experience working alongside Erik at Fugitive, his insight will prove invaluable in facilitating a smooth integration of new features into Pro-ficiency’s platform.

“What Pro-ficiency is doing to evolve performance in clinical trials is truly unique and exciting,” said Erik Guffrey, Pro-ficiency’s new Chief Technology Officer. “This team (at Pro-ficiency) is relentless about thinking differently to address problems for study teams and learners at the site. Having the resources, creative support and collaborative approach with a leadership team like this is a dream situation for any developer. We can make magic happen.”

Included in the acquisition of Fugitive Labs is a collection of ready-made platforms built specifically for clinical trial use and tested with major CROs and sponsors.

The acquisition marks the first for Pro-ficiency since their funding by NovaQuest Private Equity in 2021. Rollout plans for the acquired platforms and newly developed services will be announced in future press releases.

 

About Fugitive Labs

The Fugitive Labs core team includes a focused group of designers, engineers, and strategists skilled at combining rapid prototyping toward MVP (Minimum Viable Product) with the long-term product vision needed to achieve scale. Their areas of expertise include web and mobile development, API development, user experience, interface design and interaction design.

 

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including turn-key customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Learn more at proficiency3.wpengine.com.

 

Contact:

Collin Brooks, Marketing Manager

collin.brooks@pro-ficiency.com, +1 919.909.0420